Methods of Applied Statistics I

STA2101H F LEC9101

Week 2

September 21 2022



1. Grading scheme, Comments re texts

text website

- 2. Upcoming events
- 3. Steps in analysis; types of studies
- 4. Recap Week 1
- 5. Linear Regression Part 2: testing groups of variables, checking model assumptions, collinearity, p > n
- 6. In the news
- LM-1,2 Linear Models with R by Faraway (1st and 2nd editions)

LM (both)

highly rec'd for PhD

- ELM-1,2 Extending the Linear Model with R by Faraway (1st and 2nd editions)
- CD Principles of Applied Statistics by Cox & Donnelly
- SM Statistical Models by Davison

Upcoming Events

• Thursday Sep 22 3.30 UY 9014 Full likelihood inference for abundance from capture-recapture data Pengfei Li, U Waterloo



Applied Statistics I September 21 2022



Dear friends,

This week the Toronto Data Workshop meets on Zoom at **Thursday, 22** September, at Spm. Our guest is Dr Melina Vidoni, who is a lecturer at the Australian National University in the CECS School of Computing.

Abstract: Mining Software Repositories (MSR) is an increasingly common methodology based on extracting open, publicly available software-related data. Hence, it is considered Evidence-Based Research. Since their emergence in 2004, many investigations have analysed different aspects of MSR-based studies, such as validity of sources or data usage. This talk draws from Dr Vidoni's research experience using MSR approaches in several sources to investigate Technical Debt in different paradigms, with a special focus in scientific software. It will discuss common challenges, combining MSRs with developer surveys for mixed-methods approaches, and discuss when to consider Ethical Applications. Additionally, findings derived from MSR studies will be presented.

... upcoming events

- September 29: CANSSI Ontario Research Day
 Schedule and Registration
- Distinguished Lecture Series in Statistical Sciences
- Xihong Lin, Harvard U
 Details and Registration
- September 29 3.30 89 Chestnut Street, 3rd Floor Lessons learned from the COVID-19 Pandemic: a statistician's reflection
- September 30 3.30 UY9014 Ensemble methods for testing a global null hypothesis



2022 DLSS: Xihong Lin

Professor, Department of BiostatisticsCoordinating Director, Program in Quantitative Genomics; Harvard T.H. Chan School of Public Health; Professor of Statistics, Department of Statistics, Harvard University

Today

- 1. Grading scheme, Comments re texts
- 2. Upcoming events
- 3. Steps in analysis; types of studies
- 4. Recap Week 1
- 5. Linear Regression Part 2: testing groups of variables, checking model assumptions, collinearity, p > n
- 6. In the news

Steps in Analysis

- understand the physical background
- understand the objective
- make sure you know what the client wants
- put the problem into statistical terms
- How were the data collected:
 - are the data observational or experimental? etc.
 - is there nonresponse
 - are there missing values
 - how are the data coded
 - what are the units of measurement
 - · beware of data entry errors

LM-2 §1.1

Components of investigation

- start with a scientific question
- assess how data could shed light on this
- plan data collection
- consider of sources of variation and how careful planning can minimize their impact
- develop strategies for data analysis: modelling, computation, methods of analysis
- assess the properties of the methods and their impact on the question at hand
- communicate the results: accurately

but not pessimistically

• visualization strategies, conveyance of uncertainties

Experimental and observational studies

clinical trial

on average

- experiment is a study in which all key elements are under the control of the investigator
- in an observational study key elements cannot be controlled by the investigator
- LM-2 gives two reasons for randomizing treatment assignment
 - 1. groups are balanced on other features
 - 2. can analyse using permutation test
 - 3. elimination of personal judgement in assigning treatment to units in the experiment

randomized, double-blind

• Example: hydroxychloroquine as a treatment for COVID

ORIGINAL ARTICLE		
Observational Study of Hydroxychloroquine in H	Iospitalized	l Patients with Covid-19
Joshua Geleris, M.D., Yfei Sun, Ph.D., Jonathan Platt, Ph.D., Jason Zucker, M.D., Matthew Bald Manson, M.D., Christine Kubin, Pharm.D., R. Graham Barr, M.D., Dr.P.H., Magdalen		
Article Figures/Media	Metrics	June 18, 2020 N Engl J Med 2020; 382:2411-2418
14 References 300 Citing Articles		DOI: 10.1056/NEJMoa2012410 Chinese Translation 中文翻译
Abstract		

"In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed."

ORIGINAL ARTICLE		
A Randomized Trial of Hydroxychloroquine as Post	exposure	Prophylaxis for Covid-19
David R. Boulware, M.D., M.P.H., Matthew F. Pullen, M.D., Ananta S. Bangdiwala, M.S., Katelyn A. Pa P. Skipper, M.D., Alanna A. Nascene, B.A., Melanie R. Nicol, Pharm.D., Ph.D., Mahsa Abassi, D.C.		
Article Figures/Media	Metrics	August 6, 2020 N Engl Med 2020; 383:517-525
18 References 128 Citing Articles Letters 11 Comments		DOI: 10.1056/NEJMoa2016638

"We conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis."

"This randomized trial did not demonstrate a significant benefit of hydroxychloroquine as postexposure prophylaxis for Covid-19. "

HEALTH

Lancet, New England Journal retract Covid-19 studies, including one that raised safety concerns about malaria drugs



By Andrew Joseph 🎔 June 4, 2020



Reprints

Coc	hran	e Trusted evidence Informed decisio Better health.		S	earch	Q
Our evidence	About us	Join Cochrane	News and jobs		Cochrane Library	►
		Coronavir	us (COVID-19) resources			
		D-19, or in preve	roxychloroquine usef nting infection in peo		01 1	d to
_		C.	chrana Poviov			

Cochrane Reviews

Cochrane Reviews 🔻

Cochrane Database of Systematic Reviews Review - Intervention

Trials 🔻

Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19

Clinical Answers 👻

About 🔻

Help 🔻

Shagteshwar Singh, Hannah Ryan, Tamara Kredo, Marty Chaplin, Tom Fletcher Authors' declarations of interest Version published: 12 February 2021 Version history https://doi.org/10.1002/14651858.CD013587.pub2 C


Collapse all Expand all

Hydroxychloroquine does not reduce deaths from COVID-19, and probably does not reduce the number of people needing mechanical ventilation.

Hydroxychloroquine caused more unwanted effects than a placebo treatment, though it did not appear to increase the number of serious unwanted effects.

We do not think new studies of hydroxychloroquine should be started for treatment of COVID

... hydroxychloroquine



Cochrane Database of Systematic Reviews Editorial

Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID-19

Susan Gould, Susan L Norris Authors' declarations of interest Version published: 25 March 2021 https://doi.org/10.1002/14651858.ED000151 @

Ivermectin

() Coc	hran	C Trusted evidence Informed decisi Better health.			Search	۹
Our evidence	About us	Join Cochrane	News and jobs		Cochrane Lib	irary 🕨
	lvern	nectin for preve	nting and treatin	g COVID-19		
Published: 21 June 2022	ls iverm	nectin effective for CO	/ID-19?		(Am) score 83 Who is talking ab	
	Key me	ssages				
Authors: Popp M, Reis S, Schießer S, Hausinger Rilona, Stegeman Metzendorf M-I, Kranke P,	n M, prevent		ort the use of ivermectin n. The evidence base im		That of Syste	
Meybohm P, Skoetz N, Weibo Primary Review Group: Infectious Diseases Group,	Evaluati	ew again when their re	tinuing in 31 ongoing triz sults become available.	ils, and we will upo	date How our hea evidence ca	

model

$$\mathbf{y} = \mathbf{X}\boldsymbol{\beta} + \boldsymbol{\epsilon}$$

estimation

$$\hat{\beta}_{LS} = (X^{\mathrm{\scriptscriptstyle T}}X)^{-1}X^{\mathrm{\scriptscriptstyle T}}y$$

inference

$$\mathrm{E}(\hat{\beta}) = \beta; \quad \mathrm{var}(\hat{\beta}) = \sigma^2 (X^{\mathrm{T}} X)^{-1}$$

• if $\epsilon \sim N(0, \sigma^2 I)$:

$$\hat{\beta} \sim N(\beta, \sigma^2(X^{\mathrm{T}}X)^{-1}),$$

• estimate of σ^2 :

$$ilde{\sigma}^2 = rac{(y - X\hat{eta})^{ op}(y - X\hat{eta})}{n - p}$$

• leads to *t*-tests for individual components β_j

and confidence intervals

... Recap Week 1

- X is an $n \times p$ matrix of explanatory variables, which may be:
- measured in the sample SM Ex 8.3
 fixed by design SM Ex 8.4,
 introduced to make the model more flexible SM Ex 8.2
 X often called the design matrix in R, model.matrix
 - SPR

• *p* or *p* + 1?

summary(model1) Call: lm(formula = lpsa ~ ., data = prostate)

Residuals:

Min	1Q	Median	ЗQ	Max
-1.7331	-0.3713	-0.0170	0.4141	1.6381

Coefficients:

	Estimate	Std. Error	t value	Pr(> t)			
(Intercept)	0.669337	1.296387	0.516	0.60693			
lcavol	0.587022	0.087920	6.677	2.11e-09	***		
lweight	0.454467	0.170012	2.673	0.00896	**		
age	-0.019637	0.011173	-1.758	0.08229			
lbph	0.107054	0.058449	1.832	0.07040			
svi	0.766157	0.244309	3.136	0.00233	**		
lcp	-0.105474	0.091013	-1.159	0.24964			
gleason	0.045142	0.157465	0.287	0.77503			
pgg45	0.004525	0.004421	1.024	0.30886			
Signif. codes:							

```
0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
```

Residual standard error: 0.7084 on 88 degrees of freedom Multiple R-squared: 0.6548, Adjusted R-squared: 0.6234 F-statistic: 20.86 on 8 and 88 DF, p-value: < 2.2e-16

Applied Statistics I September 21 2022

> sumary(model1)

	Estimate	Std. Error	t value	Pr(> t)
(Intercept)	0.6693367	1.2963875	0.5163	0.606934
lcavol	0.5870218	0.0879203	6.6767	2.111e-09
lweight	0.4544674	0.1700124	2.6731	0.008955
age	-0.0196372	0.0111727	-1.7576	0.082293
lbph	0.1070540	0.0584492	1.8316	0.070398
svi	0.7661573	0.2443091	3.1360	0.002329
lcp	-0.1054743	0.0910135	-1.1589	0.249638
gleason	0.0451416	0.1574645	0.2867	0.775033
pgg45	0.0045252	0.0044212	1.0235	0.308860

n = 97, p = 9, Residual SE = 0.70842, R-Squared = 0.65

- hat matrix
- residual sum of squares RSS
- coefficient of determination R^2
- identifiability
- orthogonality

Aside: Lazy Notation

•
$$y_i = x_i^{\mathrm{T}}\beta + \epsilon_i, \quad i = 1, \dots, n$$

- $\mathbf{y} = X\boldsymbol{\beta} + \boldsymbol{\epsilon}, \quad \mathbf{y}, \boldsymbol{\epsilon} \text{ vectors of length } n$
- $y = X\beta + \epsilon$, also vectors of length *n* the lazy way

• a generic observation $y \in \mathbb{R}$ for a generic vector of covariates $x \in \mathbb{R}^{1}$ often written

$$\mathbf{y} = \mathbf{x}^{\mathrm{T}}\boldsymbol{\beta} + \boldsymbol{\epsilon}$$

or even $\mathbf{x}\beta + \epsilon$

• "where we hope there is no confusion"



• Residual sum of squares

• Decomposition of variance

• Corrected TSS $\sum (y_i - \bar{y})^2$

$$(\boldsymbol{y} - \bar{\boldsymbol{y}}\boldsymbol{1})^{\mathrm{T}}(\boldsymbol{y} - \bar{\boldsymbol{y}}\boldsymbol{1}) = (\boldsymbol{y} - \boldsymbol{X}\hat{\boldsymbol{\beta}})^{\mathrm{T}}(\boldsymbol{y} - \boldsymbol{X}\hat{\boldsymbol{\beta}}) + \hat{\boldsymbol{\beta}}^{\mathrm{T}}(\boldsymbol{X}^{\mathrm{T}}\boldsymbol{X})\hat{\boldsymbol{\beta}} - n\bar{\boldsymbol{y}}^{2}$$
$$\sum_{i=1}^{n} (\boldsymbol{y}_{i} - \bar{\boldsymbol{y}})^{2} = \sum_{i=1}^{n} (\boldsymbol{y}_{i} - \boldsymbol{x}_{i}^{\mathrm{T}}\hat{\boldsymbol{\beta}})^{2} + \hat{\boldsymbol{\beta}}_{2}^{\mathrm{T}}(\boldsymbol{X}_{2}^{\mathrm{T}}\boldsymbol{X}_{2})\hat{\boldsymbol{\beta}}_{2}$$

Applied Statistics I September 21 2022

RSS

• Residual sum of squares

• Decomposition of variance

• Corrected TSS $\sum (y_i - \bar{y})^2$

$$(\boldsymbol{y} - \bar{\boldsymbol{y}} \mathbf{1})^{\mathrm{T}} (\boldsymbol{y} - \bar{\boldsymbol{y}} \mathbf{1}) = (\boldsymbol{y} - \boldsymbol{X} \hat{\boldsymbol{\beta}})^{\mathrm{T}} (\boldsymbol{y} - \boldsymbol{X} \hat{\boldsymbol{\beta}}) + \hat{\boldsymbol{\beta}}^{\mathrm{T}} (\boldsymbol{X}^{\mathrm{T}} \boldsymbol{X}) \hat{\boldsymbol{\beta}} - n \bar{\boldsymbol{y}}^{2}$$
$$\sum_{i=1}^{n} (\boldsymbol{y}_{i} - \bar{\boldsymbol{y}})^{2} = \sum_{i=1}^{n} (\boldsymbol{y}_{i} - \boldsymbol{x}_{i}^{\mathrm{T}} \hat{\boldsymbol{\beta}})^{2} + \hat{\boldsymbol{\beta}}_{2}^{\mathrm{T}} (\boldsymbol{X}_{2}^{\mathrm{T}} \boldsymbol{X}_{2}) \hat{\boldsymbol{\beta}}_{2}$$

Applied Statistics I September 21 2022

RSS

$$\sum_{i=1}^{n} (y_i - \bar{y})^2 = (y - X\hat{\beta})^{\mathrm{T}} (y - X\hat{\beta}) + \hat{\beta}_2^{\mathrm{T}} (X_2^{\mathrm{T}} X_2) \hat{\beta}_2$$

Total SS = Residual SS + Regression SS

RSS, $SS(\hat{\beta})$

• LHS is

.

• comparison of LHS to $SS(\hat{\beta})$ reflects

$$F = {(TSS - RSS)/(p-1) \over RSS/(n-p)} ~~\sim$$

• here $\beta = (\beta_1, \beta_2, \dots, \beta_p)$, but we don't care about β_1

$$(\beta_0, \beta_1, \ldots, \beta_{p-1})$$

... comparing models

$$\sum_{i=1}^{n} (y_i - \bar{y})^2 = (y - X\hat{\beta})^{\mathrm{T}} (y - X\hat{\beta}) + \hat{\beta}^{\mathrm{T}} (X^{\mathrm{T}} X)\hat{\beta}$$

Total SS = Residual SS + Regression SS

RSS, SS $(\hat{\beta})$

- LHS is residual SS fitting only the 1-vector
- comparison of LHS to $SS(\hat{\beta})$ reflects importance of other β s, i.e. importance of explanatory variables

$$F = \frac{(TSS - RSS)/(p-1)}{RSS/(n-p)} \quad \sim F_{p-1,n-p}$$

- here $\beta = (\beta_1, \beta_2, \dots, \beta_p)$, but we don't care about β_1

 $(\beta_0, \beta_1, \ldots, \beta_p)$

Applied Statistics I September 21 2022

.

... comparing models

.

- same argument can be derived for comparing submodels
- for example, testing $(\beta_2, \beta_3, \beta_4) = (0, 0, 0)$
- fit full model $\longrightarrow RSS_{full}$; fit reduced model $\longrightarrow RSS_{red}$

$$F = \frac{(RSS_{red} - RSS_{full})/(p-q)}{RSS_{full}/(n-p)}$$

- see LM 3.1, SM §8.2 (p.367) for connection to likelihood ratio test
- when would we want to do this?

head(prostate)

#	lcavol	lweight	age	lbph	svi	lcp	gleason	pgg45	lpsa
1	-0.5798185	2.7695	50	-1.386294	0	-1.38629	6	0	-0.43078
2	-0.9942523	3.3196	58	-1.386294	0	-1.38629	6	0	-0.16252
3	-0.5108256	2.6912	74	-1.386294	0	-1.38629	7	20	-0.16252
4	-1.2039728	3.2828	58	-1.386294	0	-1.38629	6	0	-0.16252
5	0.7514161	3.4324	62	-1.386294	0	-1.38629	6	0	0.37156
6	-1.0498221	3.2288	50	-1.386294	0	-1.38629	6	0	0.76547

model1 <- lm(lpsa ~ ., data = prostate)</pre>

> summary(model1)

Coefficients:

	Estimate	Std. Error	t value	Pr(> t)	
(Intercept)	0.669337	1.296387	0.516	0.60693	
lcavol	0.587022	0.087920	6.677	2.11e-09	***
lweight	0.454467	0.170012	2.673	0.00896	**
age	-0.019637	0.011173	-1.758	0.08229	
lbph	0.107054	0.058449	1.832	0.07040	
svi	0.766157	0.244309	3.136	0.00233	**
lcp	-0.105474	0.091013	-1.159	0.24964	
gleason	0.045142	0.157465	0.287	0.77503	
pgg45	0.004525	0.004421	1.024	0.30886	

Residual standard error: 0.7084 on 88 degrees of freedom

F-statistic: 20.86 on 8 and 88 DF, p-value: < 2.2e-16

```
model3 <- lm(lpsa ~ lcavol + lweight + age + lbph + svi, data = prostate)
anova(model3,model1)
Analysis of Variance Table</pre>
```

```
Model 1: lpsa ~ lcavol + lweight + age + lbph + svi
Model 3: lpsa ~ lcavol + lweight + age + lbph + svi + lcp + gleason +
    pgg45
    Res.Df RSS Df Sum of Sq F Pr(>F)
1 91 45.526
2 88 44.163 3 1.3625 0.905 0.4421
```

does this make sense?

Factor variables

- F-tests are used when the columns to be removed form a group
- if a covariate is a factor, i.e. categorical, then lm will construct a set of dummy variables as part of the model matrix
- these variables should either all be in, or all be out

in most cases

 prostate\$gleason_factor <- factor(prostate\$gleason) levels(prostate\$gleason_factor)
 [1] "6" "7" "8" "9" model_fac <- lm(lpsa ~ .-gleason, data=prostate)

... factor variables

```
model_fac <- lm(lpsa ~ .-gleason, data=prostate)</pre>
 sumary(model_fac)
 Estimate Std. Error t value Pr(>|t|)
(Intercept)
               0.91328
                         0.84084 1.09
                                         0.2804
lcavol
               0.56999
                        0.09010
                                   6.33 1.1e-08
                         0.16961 2.76
                                         0.0070
lweight
               0.46879
              -0.02175
                         0.01136 -1.91
                                         0.0589
age
lbph
               0.09968
                         0.05898 1.69
                                         0.0946
svi
               0.74588
                         0.24740 3.01
                                         0.0034
                                  -1.31
                                         0.1941
lcp
              -0.12511
                         0.09559
               0.00499
                         0.00467 1.07
                                         0.2885
pgg45
                         0.21942 1.22
                                         0.2259
gleason_factor7 0.26761
gleason_factor8 0.49682
                         0.76927 0.65
                                         0.5201
gleason_factor9 -0.05621
                         0.50020
                                  -0.11
                                         0.9108
```

n = 97, p = 11, Residual SE = 0.70, R-Squared = 0.67

30

model_nog <- lm(lpsa ~ . - gleason - gleason_factor, data = prostate)</pre>

anova(model_fac, model_nog) # compare two models

```
Analysis of Variance Table
```

```
Model 1: lpsa ~ (lcavol + lweight + age + lbph + svi + lcp + gleason +
    pgg45 + gleason_factor) - gleason - gleason_factor
Model 2: lpsa ~ (lcavol + lweight + age + lbph + svi + lcp + gleason +
    pgg45 + gleason_factor) - gleason
    Res.Df RSS Df Sum of Sq F Pr(>F)
    1    89 44.2
    2    86 42.7 3    1.48 0.99    0.4
Applied Statistics | September 21 2022
```

... factor variables

- with designed experiments, covariates are often factors set at pre-determined levels
- see Ch 14 LM-2 (Ch 13 LM-1)

Example 8.4 in SM

- if the design is perfectly balanced, then X has orthogonal columns, and X^TX is diagonal
- so \hat{eta}_j 's are uncorrelated, and hence independent (under normality assumption)
- more generally we might have X^TX block diagonal, e.g. importance?

read Ch 3.5

Ch 3.3, 3.4, 3.6 more specialized

New Brunswick

'Nice snake, shame about the legs' and other science humour



Does humour in a scholarly paper's title make scientists want to read more?



Mia Urquhart · CBC News · Posted: Sep 20, 2022 7:00 AM AT | Last Updated: 9 hours ago

bioRxiv preprint doi: https://doi.org/10.1101/2022.03.18.484880; this version posted July 31, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

1	If this title is funny, will you cite me?
2	Citation impacts of humour and other features of article titles in ecology and evolution
3	
4	Stephen B. Heard ^{1,2} , Chloe A. Cull ^{1,3} , and Easton R. White ⁴
5	
6	¹ Dept. of Biology, University of New Brunswick, Fredericton, NB Canada E3B 5A3
7	
8	² Corresponding author. <u>sheard@unb.ca</u> ; Dept. of Biology, University of New Brunswick, PO
9	Box 4400, Fredericton, NB Canada E3B 5A3. Phone: 506-452-6047. FAX: 506-435-
10	3570.

see humour-science.pdf

Tea drinkers enjoy possible health benefits, study suggests

relaxing tea

Tea can be part of a healthy diet and people who al Cancer Institute asked about drink tea may even be a little more the tea habits of nearly a half millikely to live longer than those lion adults in the United Kingwho don't, according to a large dom, then followed them for up to etudy

es known to reduce inflammation. Past studies in China and Iapan, where green tea is popular. suggested health benefits. The new study extends the good news

cup of tea just got a bit more to the U.K.'s favourite drink: black lower risk of death from any cause

Scientists from the U.S. Nation-14 years. They adjusted for risk fac-Tea contains helpful substanc- tors such as health, socioeconomage, race and gender.

est benefit: A nine to 13 per cent Inoue-Choi, who led the study.

versus non-tea drinkers. Tea temperature, or adding milk or sugar. didn't change the results

The study, published Monday in Annals of Internal Medicine found the association held up for heart-disease deaths, but there was no clear trend for cancer ics, smoking, alcohol intake, diet, deaths, Researchers weren't sure why, but it's possible there we-Higher tea intake - two or more ren't enough cancer deaths for cups daily - was linked to a mod- any effect to show up, said Maki

A study like this, based on observing people's habits and health, can't prove cause and effect

"Observational studies like this always raise the question. Is there something else about tea drinkers that makes them healthier?" said Marion Nestle, a professor of food studies at New York University, "I like tea. It's great to drink. But a cautious interpretation seems like a good idea."

There's not enough evidence to Education.

advise changing tea habits, said Inoue-Choi

"If you drink one cup a day already. I think that is good," she said, "And please enjoy your cup of tea"

ASSOCIATED PRESS

Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science

Home + News & Events + News Releases

NEWS RELEASES

Media Advisory Monday, August 29, 2022

NIH study of tea drinkers in the UK suggests health benefits for black tea

🕾 f 🖌 +

What

A prospective study of half a million tea drinkers in the United Kingdom has shown that higher tea intake was associated with a modestly lowered risk of death. The study, led by researchers at the National Cancer Institute, part of the National Institutes of Health, is a large and comprehensive analysis of the potential mortality benefits of drinking black tea, which is the most common type of tea consumed in the U.K.

Past studies finding a modest association between higher tea intake and lower risk of death have mainly focused on Asian populations, who commonly drink green tea. Studies on black tea have yielded mixed results.

In the new study, the researchers found that people who consumed two or more cups of tea per day had a 9% to 13% lower risk of death from any cause than people who did not drink tea. Higher tea consumption was also associated with a lower risk of death from cardiovascular disease, ischemic heart disease, and stroke. The association was seen regardless of preferred tea temperature, the addition of milk or sugar, and genetic variations affecting the rate at which people metabolize caffeine.

The findings, which appear Aug. 30, 2022, in the Annals of Internal Medicine, suggest that black tea, even at higher levels of intake, can be part of a healthy diet, the researchers wrote.

The study involved 498,043 men and women between ages 40 and 69 who participated in a large cohort study called UK Biobank. The participants were followed for about 11 years, and death information came from a linked database from the UK National Health

National Canc Contact NCI Press Offi 240-760-6600 Connect w Subscribe SS Feed

Annals of Internal Medicine

ORIGINAL RESEARCH

Tea Consumption and All-Cause and Cause-Specific Mortality in the UK Biobank

A Prospective Cohort Study

Maki Inoue-Choi, PhD; Yesenia Ramirez, MPH; Marilyn C. Cornelis, PhD; Amy Berrington de González, DPhil; Neal D. Freedman, PhD; and Erikka Loftfield, PhD

Background: Tea is frequently consumed worldwide, but the association of tea drinking with mortality risk remains inconclusive in populations where black tea is the main type consumed.

Objective: To evaluate the associations of tea consumption with all-cause and cause-specific mortality and potential effect modification by genetic variation in caffeine metabolism.

Design: Prospective cohort study.

Setting: The UK Biobank.

Participants: 498 043 men and women aged 40 to 69 years who completed the baseline touchscreen questionnaire from 2006 to 2010.

Measurements: Self-reported tea intake and mortality from all causes and leading causes of death, including cancer, all cardiousaeular disease (CVD), inchemia heart disease, stroke


see tea-study.pdf

participants drinking 1 or fewer, 2 to 3, 4 to 5, 6 to 7, 8 to 9, and 10 or more cupp ert day were 0059 (95%, C), 0.91 to 1.00), 0.87 (C), 0.84 to 0.91), 0.88 (C), 0.84 to 0.91), 0.88 (C), 0.84 to 0.92, 0.91 (C), 0.86 to 0.91), 0.83 (C), 0.84 to 0.95), respectively, Inverse associations were seen for mortality from all C/O, ischernic heart disease, and troke. Findings were similar regardless of whether participants also drank coffee or not or of genetic score for cafeline metabolism.

Limitation: Potentially important aspects of tea intake (for example, portion size and tea strength) were not assessed.

Conclusion: Higher tea intake was associated with lower mortality risk among those drinking 2 or more cups per day, regardless of genetic variation in caffeine metabolism. These findings suggest that tea, even at higher levels of intake, can be part of a healthy diet.

Figure 1. Dose-response association of tea consumption and all-cause mortality* in the UK Biobank.



* Hazard ratio was adjusted for age; sex; race and ethnicity (White, Black, Asian, mixed, or other race), assessment center, Townsend deprivation score, general health status (excellent, good, fair, or poor), cancer (yes or no), cardiovascular disease (ves or no), diabetes (ves or no), BMI (kg/m²), tobacco smoking (25-level variable including current smoking status, smoking intensity (current and former smokers), time since guitting (former smokers], and cigar and pipe use [current and former smokers]); physical activity (>10 minutes of moderate or vigorous activity; days per week); alcohol intake (never drinker, former drinker, infrequent drinker [<1 drink per week], occasional drinker [>1 drink per week but <1 drink per day]. moderate daily drinker [1 to 3 drinks per day]), or heavy drinker [>3 drinks per day); coffee intake (cups per day); and dietary intake including vegetables (tablespoons per day), fruits (pieces per day), red meat (beef, lamb, and pork: 0 to 1, 1.5, 2, 2.5, 3 to 21 times per week as guintiles), and processed meat (0, <1, 1, 2 to 4, 5 to 6, and ≥7 times per week). The solid line represents hazard ratio; the dotted line represents 95% Cl.

Annals of Internal Medicine • Vol. 175 No. 9 • September 2022 1205